PODCAST · business
Citeline Podcasts
by Norstella
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
Episodes
-
Digital Health Roundup: Oura Plans IPO, FDA’s Home Health, Digital Tools For Alzheimer’s Detection
In this month: Marion Webb highlights Oura’s IPO, new partnerships, and a class-action lawsuit. George Underwood discusses digital tools for early Alzheimer’s detection and Brian Bossetta FDA’s READI-Home Innovation Challenge. Shubham Singh interviews AI longevity firm BAiO.
-
Strategic Intent: Next‑Generation Cancer Vaccines And Nouscom’s Strategy For Interception And Personalization
"Personalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions about differentiation, manufacturability, and commercial value. In this episode of Strategic Intent, In Vivo’s David Wild speaks with Marina Udier, CEO of Nouscom, about how the Basel‑based...
-
Scaling Self-Care In Asia Pacific, With APSMI's Rachmadi Joesoef and Anama O'Reilly
In this episode of Over the Counter, now also in video, HBW Insight talks to Rachmadi Joesoef, APSMI chair and CEO of Indonesian manufacturer PT Konimex, and Anama O'Reilly, who co-leads APSMI's public affairs and communications committee and heads public affairs for the ASEA zone at Opella…
more -
Drug Fix: Increasing US FDA Leadership Stability And Where All The Adcomms Have Gone
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs and Prevision Policy Founding Member Mike McCaughan consider the impact of Michael Davis and Karim Mikhail’s promotions to permanent directors of the US Food and Drug Administration’s Center for...
-
Strategic Intent: Evolving Requirements Of Life Sciences Leadership
In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.
-
Drug Fix: US FDA Commissioner Nominee Heidi Overton’s Resume And COVID-19 Vaccine Trial Changes
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman, and Editor-in-Chief Nielsen Hobbs discuss Heidi Overton’s financial and educational background as she begins navigating the path to US Food and Drug Administration commissioner confirmation…
more -
Proof Of Concept: How A Charity Bridges Lab And Clinic
Cancer Research UK is best known for funding science. But its commercial arm, Cancer Research Horizons, does something less obvious: it builds companies. This episode features Phil Masterson and Neil Jones, who run its ventures and drug discovery arms, unpacking why charities are increasingly...
-
Off-Patent, On Record: A Story Of Patients Fighting For Accessible Cystic Fibrosis Treatment
In the second episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė hears how patients with cystic fibrosis travelled to Bangladesh to collect generic version of Vertex’s highly inaccessible Trikafta. Urtė is joined by Wilna Lottering and her son Josh from…
more -
Strategic Intent: Beyond The Breakthrough - From Approval To Adoption
A medical device can work beautifully and still go nowhere. In this episode of Strategic Intent, Krishna Eluri sits down with Mark Saxton, U.S. CEO of Baird Medical, who has spent more than 25 years bringing first-of-their-kind procedural technologies to market. Their conversation digs into...
-
Making The Case For Switch, With AESGP’s Christelle Anquez-Traxler
Products like ibuprofen and loratadine are now grabbed off a pharmacy shelf without a second thought, but both started out as prescription-only medicines. The process that moves a drug from one to the other, known as Rx-to-OTC switch, is one of the most reliable forms of innovation in self-care,...
-
ZS On How AI is Reshaping The Patient's Approach to Care Delivery - a View From the US, China and Germany
A landmark three-country survey by the ZS consulting and technology firm , which shows the rapid trend towards patients' uptake of AI tools that empower them on their healthcare journeys. ZS’ Jon Roffman and Bhargav Mantha set the scene.
-
Drug Fix: MFN Finds Mid-Size Companies And More Vaccine Policy Moves
Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential differences between Most Favored Nation drug pricing agreements for small and mid-size companies and the largest pharmas (1:03), as well as...
-
【3分で解説 #世界のファーマ】第30回 米国、ジェネリック関税に国内外から懸念／BMSとAZ合併の噂 (Japanese-language podcast) Aug. 28, 2026
世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら. As US Threatens A Tariff Bomb On Generic Drugs, Will Exemptions Be Negotiated?...
-
Videocast: Goodwin’s Sophie McGrath – A Legal View Of Healthtech And Biopharma Trends
A videocast for the In Vivo podcast section, with Goodwin's Sophie McGrath - talking about healthtech and pharma trends. Innovation, investment, legal, Goodwin, Sophie McGrath, EU, Europe
-
Drug Fix: What FDA Commissioner Nominee Heidi Overton Will Mean For The Agency
Pink Sheet Editor-in-Chief Nielsen Hobbs, executive editor Derrick Gingery, and senior reporter Maaisha Osman discuss new FDA commissioner nominee Heidi Overton, her prospects for confirmation, and what her pick means for the agency. More On The Topic From The Pink Sheet FDA Commissioner Nominee...
-
Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment
One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that.
-
Strategic Intent: The Rise Of Mid-Cap Dealmakers
Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for…
more -
Building The GLP-1 Companion Category, With Beverley Law And Martina Gripp
Everyone in consumer health is talking about GLP-1s. While this new generation of weight loss drugs is firmly on the prescription-only side, industry is now thinking about how it can meet users’ needs for products that address side effects and the nutritional gaps that come with rapid weight…
more -
Drug Fix: Understanding The PDUFA VIII Revenue Cut And GDUFA IV Name Change
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the important provisions of the new prescription drug and generic drug user fee commitment letters (:53), including the revenue cut coming in PDUFA VIII (7:16), as well as the new…
more -
The State of Play in Biotech and the Decisions Shaping the Industry
Biotech leaders are navigating disciplined growth, shifting global dynamics, and rising expectations across boards, partners, and clinical teams. In this opening episode, a panel of experienced biotech executives step back to discuss where the industry truly stands, the forces shaping...
-
Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA Strategies
On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks through the distinct go-to-market strategies for an acute...
-
Drug Fix: Regulatory Nationalism And US FDA’s IND Reforms
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the impact of nationalism on the regulatory process, which entered the fray once again when news of a potential AstraZeneca-Bristol Myers Squibb merger broke (:58), as well as the US…
more -
Proof of Concept - AI in Drug Discovery
In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation & Strategy at Turbine, he's seen the problem from both…
more -
Digital Health Roundup: CE Mark For Vision-Restoring Implant, AI Chatbot Rules, MS Deal
Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification.
-
Podcast: China's Evolving Role in Global Clinical Development
How shifting perceptions and new opportunities are changing the way sponsors approach China
-
Off-Patent, On Record: View Through The Journalist's Lens With Generics Bulletin's Dave Wallace
Generics Bulletin’s senior reporter Urtė Fultinavičiūtė launches a new interview podcast series “Off-Patent, On Record.” In the inaugural episode, Urtė is joined by Dave Wallace, executive editor at Generics Bulletin, who has been covering the off-patent drug industry as a journalist and editor…
more -
Realising Growth Through Pharmacy, With Simon-Kucher’s Christian Danelund And Chris Rebholz
Consumers are turning to AI at the start of the self-care journey in growing numbers, but they do not yet trust it, the latest Better Health Report from Simon-Kucher & Partners shows. They do trust pharmacists, who can convert that trust into sales, providing crucial sales volume growth for their...
-
European Biotech At A Crossroads: How Can It Stay Competitive? Video Podcast
This Scrip video podcast brings together three European biotech leaders to discuss the challenges facing the sector, and what measures are needed to stop it falling behind the US and China and to create the next generation of European biotech champions.
-
The Next Era Of Oncology Biosimilars
Oncology biosimilars have already helped expand access to established biologic treatments while supporting more sustainable healthcare spending. As the market moves towards increasingly complex therapies, however, identifying viable opportunities will require more than monitoring patent expiries....
-
How ElevateBio Is Betting On Every Gene Editing Modality At Once
On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into the right cells. ElevateBio's chief scientific officer Amy Pooler joins In...
-
The Generics Bulletin Podcast: Summer Conferences
Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira.
-
Drug Fix: US FDA Undoes Podium Policy, Lessons From CDC, ASPR Confirmation Hearings
Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the impact of the US Food and Drug Administration clarifying that journal articles written by former commissioner Martin Makary and others were not...
-
Eisai Video Interview AT AAIC Alzheimer's Conference, July 15
Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug.
-
Scrip Deals Podcast, July 2026, with Dr. Bruce Leuchter
On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for…
more -
The Dos And Don’ts Of Health Literacy, With Self-Care Forum’s Trevor Gore
Health literacy is a phrase you hear a lot in consumer health at the moment, but it's not always clear what people mean by it, or what a company is actually supposed to do about it. In this episode of Over the Counter, HBW Insight talks to Trevor Gore, a trustee of the Self-Care Forum who spent...
-
Drug Fix: New Complete Response Letter, DTC Ad Regulations And A Potential US FDA Reorg
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the implications of potential regulations that would cement the FDA’s presumption that it can release complete response letters (:49) and effectively ban direct-to-consumer advertising...
-
Tonix’s Bet On Monoclonal Prevention Of Lyme Disease
Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceuticals with a different idea entirely: skip the vaccine and...
-
Patient Capital And Regulatory Resolve: Dr Reddy’s Chief On Building India's Innovation Backbone
In this podcast, Satish Reddy, chairman of Dr. Reddy's Laboratories, talks about deploying generic Revlimid gains strategically, building a diversified growth engine, what India must fix — regulatory science, risk capital and more — to become a serious innovation force, and learnings from China.…
more -
China’s New Data Protection Framework: Periods And Impact
In this episode of the China biopharma English-language podcast, Xu Hu talks about China’s drug regulator finalizing trial data protection measures for drugs registered in the country, and some of the impacts these may have on future licensing deals involving the China market and company…
more -
The Economic and Social Value Of Probiotics, With IPA Europe’s Rosanna Pecere
The science around the microbiome is moving fast, consumers are clearly interested, and yet the category still runs into some long-standing problems in the European Union, not least the inconsistent way the word “probiotic” itself is treated across the region. In this episode of HBW Insight’s…
more -
‘빅 드럭’ 시대 본격화…글로벌 제약 매출, 2조 달러 넘을 듯 (Korean-language podcast) June 29, 2026
비만 치료제 시장의 급성장과 일라이 릴리의 티르제파티드가 주도하는 가운데, 이벨류에이트(Evaluate)의 2026 월드 프리뷰(World Preview) 보고서에 따르면 제약 업계는 향후 몇 년 동안 새로운 매출 기록을 경신할 전망입니다(AI 기반 텍스트 음성 변환 및 음성 모방 도구의 도움을 받아 제작되었습니다)...
-
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) June 29, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月26日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 中国交易主导BIO大会热门话题；制药企业瞄准2万亿美元销售额；Apogee助力艾伯维实现愿景；桑加莫申请破产；以及对韦伯在武田制药任职期间的回顾。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Story links:...
-
Scrip's Five Must-Know Things - June 29, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended June 26, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–China deal controls a hot BIO topic; pharma eyes $2tn in sales; Apogee helps AbbVie achieve...
-
Drug Fix: US FDA’s New Guidance On One-Trial Efficacy Standard And IND Reform Pilot
Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs discuss the potential impact of the US Food and Drug Administration’s new updated guidance describing the one-trial plus confirmatory evidence standard for effectiveness (:47) and the...
-
Elevate Clinical Operations into a Board Level Strategic Advantage
Clinical operations plays a decisive role in execution quality, data integrity, cost control, and development speed, yet it is often treated as a cost centre rather than a strategic function. In this episode, Claire Riches, VP, Clinical Solutions, Citeline is joined by Executive Consultant,...
-
The Insight Room: Catching the Deadliest Cancer Earlier - Inside the PRECEDE–Azenta Partnership
Pancreatic cancer has the lowest survival rate of any major cancer — just 13%, largely because it's so hard to catch early. Changing that takes more than a lab breakthrough. It takes the unglamorous infrastructure to collect, track, and safeguard patient samples across dozens of institutions,...
-
The Yescarta Launch Examined
This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who...
-
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) June 22, 2026
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月19日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 辉瑞公司阐明肿瘤学发展方向；2026年国际生物技术大会（BIO 2026）的重点议题；GLP-1药物获取问题给肥胖症研究带来困扰；来自巴西的GLP-1药物使用洞察；以及第一季度销量前十的药物。 Story links:...
-
Scrip's Five Must-Know Things - June 22, 2026
Audio roundup of selected biopharma industry content from Scrip over the business week ended June 19, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Pfizer lays out oncology direction; key topics at BIO 2026; GLP-1 access causes problems for...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
HOSTED BY
Norstella
CATEGORIES
Loading similar podcasts...
Frequently Asked Questions
How many episodes does Citeline Podcasts have?
Citeline Podcasts currently has 625 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is Citeline Podcasts about?
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of...
How often does Citeline Podcasts release new episodes?
Citeline Podcasts releases new episodes frequently with a large back catalog of 625 episodes. Check the episode list for recent publication dates.
Where can I listen to Citeline Podcasts?
You can listen to Citeline Podcasts on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts Citeline Podcasts?
Citeline Podcasts is created and hosted by Norstella.
URL copied to clipboard!